LifeMD will begin offering Novo Nordisk’s Wegovy® oral GLP‑1 therapy, the first FDA‑approved oral formulation of the drug, through its telehealth platform. The partnership expands LifeMD’s weight‑management portfolio and positions the company to capture a larger share of the growing obesity‑treatment market.
The cash‑pay price for the 1.5 mg and 4 mg Wegovy® pills is set at $149 per month. Higher‑strength 9 mg and 25 mg doses will become available after April 15 2026 at $299 per month. LifeMD will integrate the medication into its existing NovoCare pharmacy program, allowing patients to receive prescriptions, lab work, and home delivery through a single, seamless experience.
Strategically, the move differentiates LifeMD from competitors that rely on third‑party pharmacies and offers a competitive pricing advantage. By adding an oral GLP‑1 option, LifeMD can reduce the 25 % refund rate that has historically affected weight‑management programs and improve gross margins, which were reported at 86.84 % in the most recent quarter.
The oral Wegovy® pill received FDA approval on December 22 2025, and LifeMD’s prior GLP‑1 programs have driven strong revenue growth. The partnership is expected to accelerate revenue expansion and reinforce LifeMD’s position as a leader in telehealth‑based weight management.
Novo Nordisk’s Senior Vice President of Marketing & Patient Solutions, Ed Cinca, described the oral Wegovy® pill as a “significant innovation” that enhances affordability and accessibility for patients who prefer oral therapy over injections.
Investors welcomed the announcement, citing the first oral GLP‑1 as a key differentiator and a potential driver of future growth.
The partnership is likely to generate additional revenue streams, improve margin performance through cost‑effective delivery, and strengthen LifeMD’s competitive moat in the obesity‑treatment market. However, the company will need to manage the 25 % refund rate and ensure that the higher‑strength doses are priced competitively to sustain long‑term profitability.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.